Main Article Content
Background: Polycystic Ovary Syndrome is a common female endocrinopathy. It is associated with adipokines dysfunctional secretion pattern and insulin resistance, which is considered as the main reason for its clinical feature. Wingless type1 inducible signaling pathway protein-1 is a novel adipokine that displays insulin resistance and adipose tissue inflammation where it strongly related to adipocyte accumulation and regeneration. Betatrophin has a potential role in pancreatic beta-cell proliferation and obesity and several studies showed inconsistent betatrophin levels in patients with diabetes and obesity but, its relation to polycystic ovary syndrome is unclear.
Aim: Investigation of the role of serum wingless type1 inducible signaling pathway protein-1 and betatrophin in normal weight and obese patients with polycystic ovary syndrome. Studying their association with other markers, then determine whether obesity and insulin resistance is associated with them.
Methods: Wingless type1 inducible signaling pathway protein-1 and betatrophin serum levels were measured in 44 patients with polycystic ovary syndrome (22 obese and 22 non-obese) and 44 matched control (22 obese and 22 non-obese) females using specific ELISA kits.
Results: Betatrophin and wingless type1 inducible signaling pathway protein-1 levels were elevated in the polycystic ovary syndrome group (49.4 pg/ml, 187.6 pg/ml) than in the control group (32.08 pg/ml, 108.4 pg/ml) respectively. Moreover, their levels were higher in the obese subgroup than in normal weight subgroup. There were positive correlations between wingless type1 inducible signaling pathway protein-1 and betatrophin in non-obese (r=0.89, p=0.0001***) and in obese (r=0.78, p=0.0001***) polycystic ovary syndrome groups.
Conclusion: Betatrophin and wingless type1 inducible signaling pathway protein-1 are associated with adiposity and insulin resistance in polycystic ovary syndrome. Hence wingless type1 inducible signaling pathway protein-1 and betatrophin may play a role in the incidence of polycystic ovary syndrome. They may be valuable in diagnosis and prediction of polycystic ovary syndrome patients.
Kakoly NS, Moran LJ, Teede HJ, Joham AE. Cardiometabolic risks in PCOS: A review of the current state of knowledge. Expert Review of Endocrinology & Metabolism. 2019;14(1):23-33.
Morshedzadeh N, Saedisomeolia A, Djalali M, Eshraghian MR, Hantoushzadeh S, Mahmoudi M. Resolvin D1 impacts on insulin resistance in women with polycystic ovary syndrome and healthy women. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(1): 660-4.
Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149(5):R219-27.
Cankaya S, Demir B, Aksakal SE, Dilbaz B, Demirtas C, Goktolga U. Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome. Fertility and Sterility. 2014;1;102(3):826-30.
Murahovschi V, Pivovarova O, Ilkavets I, Dmitrieva RM, Döcke S, Keyhani-Nejad F, Gögebakan Ö, Osterhoff M, Kemper M, Hornemann S, Markova M. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes. 2015;64(3):856-66.
Siddiqa A, Ahmad J, Ali A, Paracha RZ, Bibi Z, Aslam B. Structural characterization of ANGPTL8 (Betatrophin) with its interacting partner lipoprotein lipase. Computational Biology and Chemistry. 2016;61:210-20.
Pu D, Li L, Yin J, Liu R, Yang G, Liao Y, Wu Q. Circulating ANGPTL8 Is associated with the Presence of metabolic syndrome and insulin resistance in polycystic ovary syndrome young women. Mediators of Inflammation. 2019;1-10.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research. 2019;47(D1): D607-13.
Luo P, Zhang C, He Y, Yang G, Liu H, Li L. Several Circulating Biomarkers for PCOS Diagnosis. Experimental and Clinical Endocrinology & Diabetes. 2019;127(10): 645-705.
Varikasuvu SR, Panga JR, Satyanarayana MV. Circulating Angiopoietin-like 8 protein (ANGPTL8/Betatrophin) in patients with polycystic ovary syndrome: A systematic review and multi effect size meta-analysis. Gynecological Endocrinology. 2019;35(3): 190-7.
Duan Y, Feng Z, Deng H. Decreased circulating levels of betatrophin in Chinese women with polycystic ovary syndrome. Int J Clin Exp Med. 2017;10(3):5196-202.
Wang H, Du L, Wu T, Yang G, Hu W, Wang H, Yang M, Liu D, Gu HF, Zhu Z, Zheng H. Circulating betatrophin is associated with insulin resistance in humans: Cross-sectional and interventional studies in vivo and in vitro. Oncotarget. 2017;8(57):96604.
Eksi Haydardedeoglu F, Bagir GS, Haydardedeoglu B, Bozkirli E, Bakiner O, Metin K, Ertorer ME. Serum betatrophin levels are reduced in patients with full-blown polycystic ovary syndrome. Gynecological Endocrinology. 2019;35(3): 224-7.
Qu Q, Zhao D, Zhang F, Bao H, Yang Q. Serum betatrophin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome. Journal of International Medical Research. 2017;45(1):193-202.
Calan M, Yilmaz O, Kume T, Kocabas GU, Senses PY, Senses YM, Temur M, Calan OG. Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. Endocrine. 2016;53(1): 271-9.
Kahraman S, Altinova AE, Yalcin MM, Gulbahar O, Arslan B, Akturk M, Cakir N, Toruner FB. Association of serum betatrophin with fibroblast growth factor-21 in women with polycystic ovary syndrome. Journal of Endocrinological Investigation. 2018;41(9):1069-74.
Efthymiadou A, Bogiatzidou M, Kritikou D, Chrysis D. Anti-Müllerian hormone in girls with premature adrenarche: The impact of polycystic ovary syndrome history in their mothers. The Journal of pediatrics. 2019; 205:190-4.
Klimontov VV, Bulumbaeva DM, Lykov AP, Fazullina ON, Bgatova NP, Orlov NB, Pfeiffer AF, Pivovarova O, Rudovich N. Serum levels of WISP1/CCN4 in subjects with type 2 diabetes: the relationships with body fat distribution and adipose tissue dysfunction. In 2018 11th International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology (BGRSSB). IEEE. 2018;20:85-87.
Habib NS, EL-Hefnawy MH, El-Mesallamy HO. Assessment of circulating Wnt1-inducible signaling pathway protein 1 (WISP1) in obesity and type 2 diabetes mellitus patients. Archives of Pharmaceutical Sciences Ain Shams University. 2018;2(1):47-53.
Ferrand N, Béreziat V, Moldes M, Zaoui M, Larsen AK, Sabbah M. WISP1/CCN4 inhibits adipocyte differentiation through repression of PPARγ activity. Scientific Reports. 2017;7(1):1-2.
Hörbelt T, Tacke C, Markova M, de Wiza DH, Van de Velde F, Bekaert M, Van Nieuwenhove Y, Hornemann S, Rödiger M, Seebeck N, Friedl E. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia. 2018;61(9): 2054-65.
Sahin Ersoy G, Altun Ensari T, Subas S, Giray B, Simsek EE, Cevik O. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. The Journal of Maternal-fetal & Neonatal Medicine. 2017;30(8):942-946.